Search results for "CALL"

showing 10 items of 2320 documents

Diurnal Variation of Non-Arboreal Pollen in the Air in Finland

1981

Abstract This study was carried out in Jyvaskyla and Turku, in central and southern Finland, with Burkard spore traps. The average diurnal variation of all non-arboreal pollen types found in sufficient quantities is presented. A high concentration of Artemisia pollen lasting 4–8 hours was found mainly in the morning. The highest concentrations of Brassicaceae, Calluna, Cyperaceae and Rosaceae occurred during the daylight hours, often with no definite peaks. The peak occurrence of Chenopodiaceae, Compositae and Plantago pollen was around 12.00 and of Rumex from 06.00 to 10.00. The diurnal variation of Poaceae pollen varies considerably depending on the species flowering at the time. Peaks oc…

CallunaPlantagofood.ingredientbiologyDiurnal temperature variationUrticaPlant Sciencebiology.organism_classificationmedicine.disease_causefoodPollenBotanymedicineCyperaceaeRumexEcology Evolution Behavior and SystematicsMorningGrana
researchProduct

From the Strait of Gibraltar to northern Europe: Pleistocene refugia and biogeographic history of heather (Calluna vulgaris, Ericaceae)

2021

Abstract Calluna vulgaris (Ericaceae) is the most widespread and prevalent woody species of the European dry heathland, from the African side of the Strait of Gibraltar to northern Europe. However, previous biogeographic analyses of this species have ignored the western Mediterranean region, despite its preponderant role as a major glacial refugium for European biota. Here, we explore the existence of further Pleistocene glacial refugia for C. vulgaris in the Iberian Peninsula and the Strait of Gibraltar area and provide new insights into the post-glacial colonization of Europe by this emblematic heathland species. We carried out phylogeographical analyses of C. vulgaris samples from 44 loc…

CallunabiologyPleistoceneEricaceaeEcologyPlant Sciencebiology.organism_classificationEcology Evolution Behavior and SystematicsBotanical Journal of the Linnean Society
researchProduct

Plant regeneration from isolated cells ofLavandula latifolia medicus

1988

Single cells were obtained from hypocotyl-derived callus ofLavandula latifolia Medicus. Cells were plated in Murashige and Skoog medium supplemented with indoleacetic acid (IAA), benzyladenine (BA), and several IAA-BA combinations. Cell division required the simultaneous presence of IAA and BA in the culture medium, but callus formation was only achieved with 0.1 or 1 mg/liter IAA and 2 mg/liter BA. To induce organogenesis, calli were transferred to various regeneration media. Shoot-bud differentiation efficiency depended on the composition of both the callus induction and the shoot regeneration media, best results being obtained when calli grown in 1 mg/liter IAA and 2 mg/liter BA were sub…

Callus formationClinical BiochemistryLavandula latifoliaOrganogenesisPlant ScienceCell BiologyBiologybiology.organism_classificationMurashige and Skoog mediumCell cultureCallusShootBotanyComposition (visual arts)BiotechnologyDevelopmental BiologyIn Vitro Cellular & Developmental Biology
researchProduct

Patterns of Carbon-Bound Exogenous Compounds in Patients with Lung Cancer and Association with Disease Pathophysiology.

2021

Abstract Asymptomatic anthracosis is the accumulation of black carbon particles in adult human lungs. It is a common occurrence, but the pathophysiologic significance of anthracosis is debatable. Using in situ high mass resolution matrix-assisted laser desorption/ionization (MALDI) fourier-transform ion cyclotron resonance (FT-ICR) mass spectrometry imaging analysis, we discovered noxious carbon-bound exogenous compounds, such as polycyclic aromatic hydrocarbons (PAH), tobacco-specific nitrosamines, or aromatic amines, in a series of 330 patients with lung cancer in highly variable and unique patterns. The characteristic nature of carbon-bound exogenous compounds had a strong association wi…

Cancer ResearchLung NeoplasmsNitrosaminesDNA damageCarcinogenesismedicine.disease_causeMass SpectrometryTobacco UseMetabolomeTumor MicroenvironmentMedicineHumansCarcinogenesis; Carcinoma Squamous Cell/chemically induced; Carcinoma Squamous Cell/metabolism; Carcinoma Squamous Cell/pathology; Humans; Idiopathic Pulmonary Fibrosis/chemically induced; Idiopathic Pulmonary Fibrosis/metabolism; Idiopathic Pulmonary Fibrosis/pathology; Lung Neoplasms/chemically induced; Lung Neoplasms/metabolism; Lung Neoplasms/pathology; Mass Spectrometry; Metabolome; Nitrosamines/adverse effects; Polycyclic Aromatic Hydrocarbons/adverse effects; Retrospective Studies; Tobacco Use; Tumor MicroenvironmentPolycyclic Aromatic HydrocarbonsLung cancer610 Medicine & healthRetrospective StudiesAnthracosisLungbusiness.industrymedicine.diseasePathophysiologyIdiopathic Pulmonary Fibrosismedicine.anatomical_structureOncologyTumor progressionCancer researchCarcinoma Squamous CellMetabolome570 Life sciences; biologybusinessCarcinogenesis
researchProduct

Algorithmically deduced FREM2 molecular pathway is a potent grade and survival biomarker of human gliomas

2021

Gliomas are the most common malignant brain tumors with high mortality rates. Recently we showed that the FREM2 gene has a role in glioblastoma progression. Here we reconstructed the FREM2 molecular pathway using the human interactome model. We assessed the biomarker capacity of FREM2 expression and its pathway as the overall survival (OS) and progression-free survival (PFS) biomarkers. To this end, we used three literature and one experimental RNA sequencing datasets collectively covering 566 glioblastomas (GBM) and 1097 low-grade gliomas (LGG). The activation level of deduced FREM2 pathway showed strong biomarker characteristics and significantly outperformed the FREM2 expression level it…

Cancer ResearchMutantnapoved preživetjaBiologyTranscriptometranscriptomicsGliomagliomagliommedicineGeneRC254-282udc:616-006glioblastomWild typeglioblastomaNeoplasms. Tumors. Oncology. Including cancer and carcinogenssurvival prognosisMolecular pathway<i>FREM2</i>medicine.diseasenervous system diseasesOncologyCancer researchBiomarker (medicine)algorithmically deduced molecular pathwayFREM2Glioblastoma
researchProduct

Home pesticide exposures and risk of childhood leukemia: Findings from the childhood leukemia international consortium

2015

Some previous studies have suggested that home pesticide exposure before birth and during a child's early years may increase the risk of childhood leukemia. To further investigate this, we pooled individual level data from 12 case-control studies in the Childhood Leukemia International Consortium. Exposure data were harmonized into compatible formats. Pooled analyses were undertaken using multivariable unconditional logistic regression. The odds ratio (ORs) for acute lymphoblastic leukemia (ALL) associated with any pesticide exposure shortly before conception, during pregnancy and after birth were 1.39 (95% confidence interval [CI]: 1.25, 1.55) (using 2,785 cases and 3,635 controls), 1.43 (…

Cancer ResearchPediatricsmedicine.medical_specialtyChildhood leukemiabusiness.industryCase-control studyMyeloid leukemiaOdds ratioEnvironmental exposuremedicine.diseaseConfidence intervalLeukemiaOncologyRecall biasmedicinebusinessInternational Journal of Cancer
researchProduct

Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a pr…

2013

PURPOSE To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial. PATIENTS AND METHODS Patients age 18 to 45 years were randomly assigned to receive either the GnRHa triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) concomitantly with alkylating agents containing chemotherapy. The primary end point was the premature ovarian failure (POF) rate (follicle-stimulating hormone [FSH] ≥ 40 IU/L) after 1 year of follow-up. Results Eighty-four of 129 randomly assigned patients …

Cancer ResearchTime FactorsLymphomamedicine.medical_treatmentGonadotropin-Releasing Hormone -- agonistsPrimary Ovarian InsufficiencyTriptorelin Pamoate -- therapeutic uselaw.inventionGonadotropin-Releasing HormoneGynécologieRandomized controlled triallawAntineoplastic Combined Chemotherapy ProtocolsClinical endpointBiological Markers -- bloodNorethindrone -- therapeutic useProspective StudiesTreatment FailureProspective cohort studyTriptorelin PamoateEstradiolLymphoma Non-HodgkinLymphoma -- drug therapyMiddle AgedTriptorelinHodgkin DiseasePremature ovarian failureLuteolytic AgentsOncologyHodgkin Disease -- drug therapyDrug Therapy CombinationFemaleEstradiol -- bloodmedicine.drugAdultAntineoplastic Combined Chemotherapy Protocols -- administration & dosage -- adverse effectsmedicine.medical_specialtyNorethisteronemedicine.drug_classUrologyFollicle Stimulating Hormone -- bloodGonadotropin-releasing hormone agonistmedicineHumansGynecologyChemotherapybusiness.industrymedicine.diseaseLuteolytic Agents -- therapeutic useCancérologieLymphoma Non-Hodgkin -- drug therapyPremenopausePrimary Ovarian Insufficiency -- blood -- chemically induced -- prevention & controlFollicle Stimulating HormoneNorethindronebusinessBiomarkersFollow-Up Studies
researchProduct

Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial

2020

4006 Background: Local control in locally advanced rectal cancer (LARC) has improved. However, systemic relapses remain high even with postoperative chemotherapy, possibly due to low compliance. Short-course radiotherapy (SCRT) followed by delayed surgery with, in the waiting period, chemotherapy, may lead to better compliance, downstaging and fewer distant metastases. The main objective of the international multicenter phase III RAPIDO trial is to decrease Disease-related Treatment Failure (DrTF), defined as locoregional failure, distant metastasis, a new primary colon tumor or treatment-related death, by reducing the risk of systemic relapse without compromising local control. Methods: M…

Cancer Researchmedicine.medical_specialtyChemotherapyPostoperative chemotherapyColorectal cancerbusiness.industrymedicine.medical_treatmentLocally advancedmedicine.diseaseSurgery03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesismedicinebusiness030215 immunologyShort course radiotherapy
researchProduct

A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally …

2019

TPS2655 Background: In patients (pts) with locally advanced or metastatic G/GEJ cancer, fluoropyrimidine- and platinum (plt)-based combination chemotherapy is first-line standard of care. Despite improvement in chemotherapy regimens, outcomes are poor and survival remains low. Tislelizumab, an investigational anti-PD-1 antibody, was engineered to minimize binding of FcγR on macrophages in order to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. Previous reports suggested tislelizumab, as a single agent and in combination with chemotherapy, was generally well tolerated and had antitumor activity in pts with advanced so…

Cancer Researchmedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentLocally advancedCancerCombination chemotherapyPlacebomedicine.diseaseGastroesophageal JunctionGastroenterology03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineMedicineAdenocarcinomaIn patientbusiness030215 immunologyJournal of Clinical Oncology
researchProduct

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic ga…

2020

TPS458 Background: First-line standard of care in patients with locally advanced or metastatic G/GEJ adenocarcinoma is fluoropyrimidine- and platinum (plat)-based combination chemotherapy. Despite improved chemotherapy regimens, outcomes remain poor and survival is low. Tislelizumab, an investigational humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1, was engineered to minimize binding of FcγR on macrophages in order to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. Previous reports from early phase studies suggested tislelizumab, as a single agent and combined with chemotherapy,…

Cancer Researchmedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentLocally advancedCombination chemotherapymedicine.diseaseGastroesophageal JunctionPlaceboGastroenterologyFirst line therapyOncologyInternal medicinemedicineAdenocarcinomaIn patientbusinessJournal of Clinical Oncology
researchProduct